News About: Pharm. Industry


2 products of ‘Amosartan,’ Hanmi’s modified medicines,’ record highest annual manufacturing performance with KRW 57.5 billion

There were 9 products making more than KRW 10 billion last year out of pharmaceutical products approved as incrementally modified drug, and 2 products of Amosartan, Hanmi Pharm’...

Medicine recorded highest manufacturing performance is ‘Gaswhalmyungsu Soln’

A product with the highest manufacturing performance was ‘Gaswhalmyungsu Soln,’ a Dong Wha Pharm’s digestive medicine.  In addition, 5 OTC medicines including Daewoong Pharmaceutical’s Ursa Tab 1mg were researched to...

Boryung Pharm’s ‘Kanarb Tab’ recording highest manufacturing performance last year among Korean new drugs

Among pharmaceutical products approved as new drug developed in Korea, a product which recorded the highest sales was ‘Kanarb Tab,’ a Boryung Pharm’s antihypertensive. In addition, among the 26 new drugs developed in...

Korean pharmaceutical market size was KRW 21.7256 trillion last year, increased by 12.9% compared to year before

The last year’s Korean pharmaceutical market was worth of KRW 21.7256 trillion increased by 12.9% compared to the year before, and the manufacturing performance of biologics also exceeded KRW 2 trillion. Moreover, the...

‘Unchanged’ negative recognition about clinical trials, ‘clinical trial = Maruta’?

In order to study recognition towards clinical trials, the Korea National Enterprise for Clinical Trials(Director Dong-Hyun Ji) revealed a result of the national survey about recognition on clinical trials with 1,000 ...

Yuhan Corporation acquires ‘Sovaldi’ & ‘Harvoni’ license worth of KRW 120 billion a year

In the official notice on the 5th, Yuhan Corporation announced it signed an exclusive sales agreement of ‘Sovaldi’ and ‘Harvoni,’ hepatitis C treatments, in Korea with U.S. Gilead. Gilead’s ‘Sovaldi’ and ‘Harvoni’ sa...

Hanmi’s women executive ratio reaches 24%, 10 times higher than average of the top Korean companies

The Hanmi Pharm’s women executive ratio reportedly was close to 24%. The ratio is a figure that is 10 times higher than 2.4%, the average of the top 10 Korean large companies(referencing Chaebul.com on 4 April 2017). ...

Handok completes construction of plaster factory, firming foundation to become total healthcare company

After getting ‘Ketotop,’ an attachable arthritis treatment, by acquiring the Pacific Pharmaceuticals’ pharmaceutical business in 2014, Handok has once raised competitiveness in the penetration product field by constru...

Chong Kun Dang runs new global drug for treatment of dyslipidemia

As new clinical trial results of dyslipidemia treatment were recently revealed in the U.S., ‘CKD-519’ being developed by Chong Kun Dang has raised expectations. CKD-519, a new dyslipidemia drug with a new mechanism t...

Increase of approvals for OTC drugs

It was observed approvals for OTC medicines, which have been slow lately, are increasing this year. According to the Ministry of Food and Drug Safety(MFDS), there were 1,016 pharmaceutical products newly approved bet...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.